News | Contrast Media | January 19, 2018

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents

Focus will be on hospital-based products that could benefit from reduced renal toxicity

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents

January 19, 2018 — Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity. Through this new, internally-funded program, Ligand intends to advance products toward proof-of-concept, followed by selling or out-licensing them for further development and commercialization. The program will leverage Ligand’s patented Captisol technology, as well as data and intellectual property obtained through its acquisition of Verrow Pharmaceuticals, a privately-held Lenexa, Kansas-based medical invention company that Ligand acquired in January 2018 for $2 million in cash plus earnouts.

Ligand CEO John Higgins explained that contrast agents are an important component of the diagnostic imaging market, however they can be toxic and are known to cause kidney damage in some patients. He added that Captisol is a specialized cyclodextrin that plays a role in protecting kidneys from the damaging effects of these agents. Captisol-enabled (CE) iohexol, marketed as Omnipaque by GE Healthcare, has been shown to prevent nephrotoxicity by more than 50 percent in animal models.1

The company said the initial internal program is focused on a CE formulation of iohexol given the large global market, lack of alternatives and focused development path for use in the cardiovascular imaging setting. The initial CE-iohexol program will focus on partnering-enabling studies, with an estimated $6 million of program spend by Ligand over approximately three years.

For more information: www.ligand.com

References

1. Rowe ES, et al. Journal of Neuroimaging 2016; 26(5):511-8

Related Content

At #ACC.19, Siemens unveiled a version of its go.Top platform optimized for cardiovascular imaging. The newly packaged scanner can generate the data needed to do CT-based FFR (fractional flow reserve).

At #ACC.19, Siemens unveiled a version of its go.Top platform optimized for cardiovascular imaging. The newly packaged scanner can generate the data needed to do CT-based FFR (fractional flow reserve). Photo by Greg Freiherr

Feature | Cardiac Imaging | March 22, 2019 | By Greg Freiherr
Reflecting a trend toward the increased use of ...
SyncVision iFR Co-registration from Philips Healthcare maps iFR pressure readings onto angiogram.

SyncVision iFR Co-registration from Philips Healthcare maps iFR pressure readings onto angiogram. Results from an international study presented at #ACC19 show that pressure readings in coronary arteries may identify locations of stenoses remaining after cardiac cath interventions.

Feature | Cardiac Imaging | March 18, 2019 | By Greg Freiherr
As many as one in four patients who undergo cath lab interventions can benefit from a technology that identifies the
Jennifer N. A. Silva, M.D., a pediatric cardiologist at Washington University School of Medicine in Saint Louis, Mo., describes “mixed reality” at ACC19 Future Hub.

Jennifer N. A. Silva, M.D., a pediatric cardiologist at Washington University School of Medicine in Saint Louis, Mo., describes “mixed reality” at ACC19 Future Hub.

Feature | Cardiac Imaging | March 17, 2019 | By Greg Freiherr
Virtual reality (VR) and its less immersive kin, augmented reality (AR), are gaining traction in some medical applica
WVU cardiology chief Partho Sengupta, M.D., describes at ACC 2019 how artificial intelligence already helps cardiologists in echocardiography.

WVU cardiology chief Partho Sengupta, M.D., describes at ACC 2019 how artificial intelligence already helps cardiologists in echocardiography. Photo by Greg Freiherr

Feature | Cardiac Imaging | March 16, 2019 | By Greg Freiherr
Machine learning is already having an enormous impact on cardiology, automatically calculating measurements in echoca
Podcast | Cardiac Imaging | March 15, 2019
Debate About Coronary Testing Highlights ACC Session

Collage depicts broad applications in machine learning or deep learning (DL) that can be applied to advanced medical imaging technologies. Size of the liver and its fat fraction — 22 percent — (top middle in collage) can be quantified automatically using an algorithm developed by Dr. Albert Hsiao and his team at the University of California San Diego. This and other information that might be mined by DL algorithms from CT and MR images could help personalize patients’ treatment. Collage provided by Albert Hsiao

Feature | Cardiac Imaging | March 12, 2019 | By Greg Freiherr
Acquiring these data could change patient management
Podcast | Cardiac Imaging | March 12, 2019
How smart algorithms might reduce the burden of modern practice
Podcast | Cardiac Imaging | March 08, 2019
Why CT angiography cannot replace invasive angiography
Podcast | Cardiac Imaging | March 04, 2019
AI, Mobile Technologies Are Changing How We Think About Cardiac Disease
Videos | Cardiac Imaging | September 10, 2018
Leslee Shaw, Ph.D., professor of cardiology and rad
Overlay Init